Screening for Conditions by Electronic Nose Technology (SCENT III) (Clinical Trial Not Allowed)
Federal funding opportunity RFA-TR-26-001 from National Institutes of Health.
View forecast on Grants.gov →Forecasted — not yet open
- Posted
- September 29, 2025
- Closes
- See announcement
- Cost sharing
- No
- Instrument
- Cooperative Agreement
- Assistance listing
- 93.350
- Category
- Health
Program funding history
Awards made under Assistance Listing 93.350 across FY2024–FY2026, from public federal spending records.
- FY2024 obligated
- $588.2M
- FY2025 obligated
- $599.3M
- FY2026 (to date) obligated
- $281.4M
- Awards in window
- 886
Top recipients: Vanderbilt University Medical Center, Regents of the University of Michigan, University of Pittsburgh - of the Commonwealth System of Higher Education, Icahn School of Medicine at Mount Sinai, The Johns Hopkins University
Source: USAspending.gov · refreshed July 2026
Synopsis
This NOFO seeks to develop electronic nose technologies that mimic the olfactory system, leading to a robust diagnostic platform subject to validation and regulatory approval. A previous iteration demonstrated the feasibility of developing safe and effective biosensing technologies for volatile organic compound (VOC) signatures from human skin through systems engineering and artificial intelligence. VOCs are biomarkers that underlie the effects of a wide array of diseases. Under this iteration of the NOFO, improved sensing, detection, and analytical technologies will be developed for integration into tools for disease diagnosis and monitoring in everyday settings. These novel technologies will complement traditional blood analysis and other invasive, expensive, and highly technical procedures to monitor the onset, progression, and resolution of disease.
NCATS’ vision is to bring more treatments for all people more quickly. The electronic nose platform is noninvasive and makes diagnosis in real time, in situ. This NOFO seeks to improve the translation of existing knowledge for the prevention and treatment of various diseases conditions.
Grant authorities that allow the National Center for Advancing Translational Science (NCATS) to forecast this opportunity are as follows: 42 U.S. Code § 287a - Cures Acceleration Network.
Who can apply
- Independent school districts
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Native American tribal governments (Federally recognized)
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
- Public and State controlled institutions of higher education
- City or township governments
- Private institutions of higher education
- County governments
- State governments
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Native American tribal organizations (other than Federally recognized tribal governments)
- Small businesses
Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).
How to apply
Applications go through the official government listing. Grants Radar links you straight to the source.
Get grants like this every Tuesday — free
One email a week: the biggest new federal grants and what’s closing soon. Unsubscribe in one click.
Similar grants
- Feasibility Clinical Trials of Mind and Body Interventions for NCCIH High Priority Research Topics (R34 Clinical Trial Required)
- Data Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Mind and Body Interventions (Collaborative U24 Clinical Trial Required)
- Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)
- Limited Competition: Small Grant Program for the NCATS Clinical and Translational Science Award (CTSA) Program (R03 Clinical Trial Optional)
- Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)
- Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)
Never miss a funding deadline again
Grants Radar sends AI-enriched alerts on federal grants and contracts matched to what you do. Founding seats are limited and locked for life.
Get funding alerts